Editorial Volume 11, Issue 2 pp 291—292

Hormone therapy outcome in lymphedema

class="figure-viewer-img"

Figure 1. Tamoxifen treatment leads to lymphatic dysfunction and aggravates lymphedema. Tamoxifen inhibits estrogen binding to its receptor ERα on lymphatic endothelial cells to block both genomic and non-genomic pathways. After long-term delivery, the blockade of ERα by hormone therapy leads to lymphatic dilatation and leakage, the main features of lymphatic shape in lymphedema.